DIO Valuation

Is A039840 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A039840 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A039840 (₩16470) is trading above our estimate of fair value (₩3233.47)

Significantly Below Fair Value: A039840 is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for A039840?

Key metric: As A039840 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A039840. This is calculated by dividing A039840's market cap by their current revenue.
What is A039840's PS Ratio?
PS Ratio2x
Sales₩121.26b
Market Cap₩246.75b

Price to Sales Ratio vs Peers

How does A039840's PS Ratio compare to its peers?

The above table shows the PS ratio for A039840 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7.8x
A150840 IntroMedic
27.9xn/a₩223.7b
A043150 Value Added Technology
0.8x8.5%₩303.0b
A100120 Vieworks
0.9x9.6%₩192.8b
A041830 InBodyLtd
1.6x11.2%₩295.7b
2x17.4%₩246.7b

Price-To-Sales vs Peers: A039840 is expensive based on its Price-To-Sales Ratio (2x) compared to the peer average (1.1x).


Price to Sales Ratio vs Industry

How does A039840's PS Ratio compare vs other companies in the KR Medical Equipment Industry?

2 CompaniesPrice / SalesEstimated GrowthMarket Cap
A008490 Suheung
0.2x6.9%US$105.85m
0.3xn/aUS$24.35m
No more companies available in this PS range
A039840 2.0xIndustry Avg. 2.1xNo. of Companies14PS0246810+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: A039840 is good value based on its Price-To-Sales Ratio (2x) compared to the KR Medical Equipment industry average (2.1x).


Price to Sales Ratio vs Fair Ratio

What is A039840's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A039840 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2x
Fair PS Ratio3.6x

Price-To-Sales vs Fair Ratio: A039840 is good value based on its Price-To-Sales Ratio (2x) compared to the estimated Fair Price-To-Sales Ratio (3.6x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst A039840 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₩16,470.00
₩21,666.67
+31.6%
10.9%₩25,000.00₩20,000.00n/a3
Nov ’25₩16,290.00
₩20,600.00
+26.5%
4.1%₩21,800.00₩20,000.00n/a3
Oct ’25₩16,350.00
₩20,600.00
+26.0%
4.1%₩21,800.00₩20,000.00n/a3
Sep ’25₩16,200.00
₩23,600.00
+45.7%
16.5%₩29,000.00₩20,000.00n/a3
Aug ’25₩19,360.00
₩29,500.00
+52.4%
1.7%₩30,000.00₩29,000.00n/a2
Jul ’25₩19,050.00
₩32,000.00
+68.0%
11.1%₩37,000.00₩29,000.00n/a3
Jun ’25₩19,380.00
₩32,000.00
+65.1%
11.1%₩37,000.00₩29,000.00n/a3
May ’25₩20,600.00
₩36,750.00
+78.4%
4.0%₩39,000.00₩35,000.00n/a4
Apr ’25₩22,500.00
₩36,750.00
+63.3%
4.0%₩39,000.00₩35,000.00n/a4
Mar ’25₩21,100.00
₩36,750.00
+74.2%
4.0%₩39,000.00₩35,000.00n/a4
Feb ’25₩19,380.00
₩38,200.00
+97.1%
8.3%₩44,000.00₩35,000.00n/a5
Jan ’25₩22,400.00
₩38,200.00
+70.5%
8.3%₩44,000.00₩35,000.00n/a5
Dec ’24₩21,100.00
₩38,200.00
+81.0%
8.3%₩44,000.00₩35,000.00n/a5
Nov ’24₩23,600.00
₩42,600.00
+80.5%
6.7%₩47,000.00₩39,000.00₩16,290.005
Oct ’24₩25,300.00
₩43,600.00
+72.3%
5.1%₩47,000.00₩40,000.00₩16,350.005
Sep ’24₩29,950.00
₩43,600.00
+45.6%
5.1%₩47,000.00₩40,000.00₩16,200.005
Aug ’24₩31,200.00
₩43,600.00
+39.7%
5.1%₩47,000.00₩40,000.00₩19,360.005
Jul ’24₩33,950.00
₩43,333.33
+27.6%
6.6%₩47,000.00₩40,000.00₩19,050.003
Jun ’24₩29,000.00
₩38,250.00
+31.9%
23.9%₩47,000.00₩23,000.00₩19,380.004
May ’24₩29,700.00
₩38,250.00
+28.8%
23.9%₩47,000.00₩23,000.00₩20,600.004
Apr ’24₩24,850.00
₩31,250.00
+25.8%
15.7%₩35,000.00₩23,000.00₩22,500.004
Mar ’24₩24,400.00
₩33,000.00
+35.2%
17.0%₩40,000.00₩23,000.00₩21,100.005
Feb ’24₩21,850.00
₩34,500.00
+57.9%
20.1%₩40,000.00₩23,000.00₩19,380.004
Jan ’24₩19,700.00
₩34,500.00
+75.1%
20.1%₩40,000.00₩23,000.00₩22,400.004
Dec ’23₩19,600.00
₩34,500.00
+76.0%
20.1%₩40,000.00₩23,000.00₩21,100.004
Nov ’23₩19,800.00
₩38,333.33
+93.6%
6.1%₩40,000.00₩35,000.00₩23,600.003

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies